Rebecca Mehrwerth

Rebecca (Becca) Mehrwerth joined Epizyme in August 2021 as the Senior Vice President of Market Access & Customer Engagement and was appointed Head of Commercial in January 2022. A proven commercial leader with more than 20 years of experience building commercial teams and leading product launches, Becca previously led the U.S. Customer Engagement team within GlaxoSmithKline’s (GSK) Oncology Business Unit charged with advancing its go-to-market strategy for its newly formed business unit following its acquisition of TESARO. Rebecca spent four years at TESARO where she held roles of increasing responsibility, from Vice President of U.S. sales, leading the launches of VARUBI®, an oral antiemetic, and ZEJULA®, an oral oncolytic for ovarian cancer to Senior Vice President of U.S. Customer Engagement where she provided strategic guidance over multiple customer facing teams generating more than $200 million in sales. Prior to TESARO, she held various commercial roles of increasing responsibility at Celgene, Abraxis, MGI Pharma, Inc., and Bristol-Myers Squibb.

Becca holds a B.B.A. in Finance from Texas State University. She currently serves as the “Biopharma Executive in Residence” for the University of Minnesota where she mentors and engages directly with start-ups, providing support for their products or business ideas, from value propositions to business model development. When not traveling for work, Becca loves spending time on the farm with her family, including husband Kevin and their two children, Lauren and Max. Together, they enjoy traveling and have a goal of visiting as many National Parks as possible.